|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 29, 2016 ) Restless legs syndrome increases at night when the patient is at rest. RLS are common in both, male and female; however the disease has its highest impact on woman who are elderly or in some cases woman with the age 35 to 50 years. Some of the most common symptoms of the restless legs syndrome are continue itching and pain in the legs, and unusual sleep pattern. The restless legs syndrome affects the quality of life of the person suffering from the disease.
To know more about Restless Legs Syndrome Market visit: https://www.psmarketresearch.com/market-analysis/restless-legs-syndrome-market
The exact treatment of this disease is not present till now. However the available drug in the market helps in the indicative treatment of the disease. Some of the drug in the restless legs syndrome market such as sulfonamide by safinamide by Newron Pharmaceuticals reduces the symptoms by novel action such as potent, reversible and selective inhibition of MAO-B, without disturbing the MAO-A and dopamine uptake. This enhances the glutamate release and dopaminergic function of the patients; it also reduces the dopamine degradation. One other drug: SER-214 manufacture by Serina is used widely in the restless legs syndrome treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology this drug can be combined with the polymer and transported to the patients.
The currently available drugs in restless legs syndrome can only delivered to target specific patients for symptomatic relief only. Moreover, some of the adverse effects such as nervous system disorders that include headache, dizziness, sedation, nausea, flatulence and dry mouth. Psychiatric disorders, including decreased libido and depression. Metabolism and nutritional disorders, including increased appetite and weight gain; ear disorder, labyrinth disorders and other common disorders such as irritability, fatigue, and peripheral edema are related with the use of these drugs. Thus the treatment procedure for the restless legs syndrome is still not very popular and not adopted by the healthcare service provider on a larger part. The development of new drugs that have higher efficiency and minimal side effect would be highly appreciated in the restless legs syndrome treatment market.
Request for TOC of Restless Legs Syndrome Market: https://www.psmarketresearch.com/enquiry-form.php?enqid=234&title=TOC
Some of the major players operating in the global restless legs syndrome market include, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.
About P&S Market Research
P&S Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries.
With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our publication. Our research assists our client in identifying new and different windows of opportunity and frame informed and customized strategies for expansion in different regions.
Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Email: enquiry@psmarketresearch.com
US/ Canada Toll-Free: 1-888-778-7886
Web: https://www.psmarketresearch.com
P&S Market Research
Abhishek
18887787886
enquiry@psmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
